natgillin/translations-raw huggingface dataset:
Following intravenous administration, choriogonadotropin alfa is distributed to the extracellular fluid space with a distribution halflife of around 4.5 hours.
Nakon intravenske primjene koriogonadotropin alfa raspodjeljuje se u prostoru izvanstanične tekućine uz poluvrijeme raspodjele od oko 4,5 sati.
Following intravenous administration, mean plasma clearance is approximately 9 l/h.
Nakon intravenske primjene srednja vrijednost klirensa iz plazme je približno 9 l/h.
Following intravenous administration, naloxone is rapidly distributed (distribution half- life ~ 4 minutes).
Nakon intravenske primjene, nalokson se brzo distribuira (poluvrijeme distribucije ~ 4 minute).
Following intravenous administration, plasma concentrations of pixantrone reached the maximal concentration at the end of infusion and then declined poly-exponentially.
Nakon intravenske primjene koncentracija piksantrona u plazmi doseže svoj maksimum na kraju infuzije i zatim postepeno opada polieksponencijalno.
Following intravenous administration, the apparent volume of distribution was about 0.8 l/kg, indicating that abacavir penetrates freely into body tissues.
Nakon intravenske primjene, prividni volumen raspodjele je oko 0,8 l/kg, što pokazuje da abakavir slobodno ulazi u tjelesna tkiva.
Following intravenous and oral administration, the terminal t1/2s were similar at 3.5 and 4.1 hours respectively.
Nakon intravenske i peroralne aplikacije, završna poluvremena eliminacije (t1/2) su bila vrlo slična, 3,5 i 4,1 sata ovisno o načinu davanja.
Following intravenous bolus injection of 10 + 10 U in patients with acute myocardial infarction reteplase antigen is distributed in plasma with a dominant half-life (t1/2) of 185 min and eliminated with a terminal half-life (t1/2ß) of 5.5 hours12.5 min at a clearance rate of 12125 ml/min.
U bolesnika s akutnim infarktom miokarda nakon intravenske bolusne injekcije od 10 + 10 U, antigen reteplaze raspodjeljuje se u plazmi s dominantnim poluvijekom (t1/2) od 185 minuta, a eliminira s krajnjim poluvijekom (t1/2ß) od 5,5 sati12,5 minuta pri klirensu od 12125 ml/minuta.
Following intravenous dosing the volume of distribution at steady-state (Vss) was 31.7 l/kg.
Nakon intravenoznog doziranja volumen raspodjele u mirnom stanju bio je 31,7 l/kg.
Following intravenous infusion, the apparent steady-state volume of distribution was 0.6 to 0.8 l/kg in healthy subjects.
Nakon intravenske infuzije prividni volumen distribucije u stanju dinamičke ravnoteže iznosio je od 0,6 do 0,8 l/kg u zdravih ispitanika.
Following intravenous infusion, the recovery of total radioactivity is 81 %, and the respective recoveries in urine and faeces are 68% and 12%.
Nakon intravenske infuzije oporavak ukupne radioaktivnosti iznosi 81%, dok oporavak u mokraći i stolici iznosi 68%, odnosno 12%.
Following intravnous bolus administration of 30 mg tenecteplase in patients with acute myocardial infarction, the initially estimated tenecteplase plasma concentration was 6.45 ± 3.60 µg/mL (mean ± SD) .
Nakon intravenske primjene bolusa od 30 mg tenekteplaze kod bolesnika s akutnim infarktom miokarda, početna procjena koncentracije tenekteplaze u plazmi bila je 6.45 ± 3.60 µg/mL (srednja vrijednost ± SD).
Following intra­arterial injection of liraglutide to rabbits, slight to moderate haemorrhage, erythema and swelling at the injection site were observed.
Nakon injekcije liraglutida u arteriju kod kunića je opažena pojava laganog do umjerenog krvarenja, eritema i oticanja na mjestu injiciranja.
Following local intramuscular injection of NeuroBloc serious adverse events that may have been due to systemic effects of Botulinum Toxin Type B, were observed in 12% of adverse reaction cases reported during the post-marketing experience (including the following adverse reactions: dry mouth, dysphagia and blurred vision).
Nakon lokalne intramuskularne injekcije NeuroBloca ozbiljni štetni događaji koji su se možda razvili zbog sistemskih učinaka botulinskog toksina tipa B opaženi su u 12% slučajeva nuspojava prijavljenih tijekom iskustva nakon stavljanja lijeka u promet (uključujući sljedeće nuspojave: suha usta, disfagija i zamagljen vid).
Following long-term treatment, fentanyl may cause withdrawal in the new-born infant.
Nakon dugotrajnog liječenja fentanil može uzrokovati ustezanje kod novorođenčadi.
Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the (mean ± SD) steady state plasma emtricitabine peak concentrations (Cmax) were 1.8 ± 0.7 μg/mL and the area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was 10.0 ± 3.1 μg•h/mL.
20 ispitanika zaraţenih virusom HIV-1, vršne koncentracije (Cmax) (srednja vrijednost ± SD) emtricitabina u plazmi pri dinamičkoj ravnoteţi bile su 1,8 ± 0,7 µg/ml, a površina ispod krivulje koncentracija-vrijeme tijekom 24-satnog intervala doziranja (AUC) bila je 10,0 ± 3,1 µg•h/ml.
Following multiple doses of CE 0.45 mg/bazedoxifene 20 mg, the mean steady state pharmacokinetic parameters for CE and bazedoxifene (baseline adjusted for total estrone) are summarised below.
Nakon višekratnih doza 0,45 mg KE/20 mg bazedoksifena, srednje vrijednosti farmakokinetičkih parametara u stanju mirovanja za KE i bazedoksifen (početna vrijednost prilagođena za ukupni estron) su sumirani u nastavku.
Following multiple monthly doses, pasireotide intramuscular use demonstrates approximately dose-proportional pharmacokinetic exposures in the dose range of 20 mg to 60 mg every 4 weeks in patients with acromegaly.
Nakon višestrukih mjesečnih doza, pasireotid primijenjen intramuskularno pokazuje otprilike dozi proporcionalne farmakokinetičke izloženosti u rasponu doze od 20 mg do 60 mg svaka 4 tjedna u bolesnika s akromegalijom.
Following multiple oral administrations, the steady state is reached by the third daily dose.
Nakon višekratne oralne primjene, stabilno se stanje postiže trećinom dnevne doze.
Following multiple oral doses of abacavir 300 mg twice a day there is no significant accumulation of abacavir.
Nakon davanja višekratnih oralnih doza abakavira od 300 mg dvaput na dan nije bilo značajnog nakupljanja abakavira.
Following multiple oral doses of ADENURIC, the Cmax and AUC were 24% and 12% higher in females than in males, respectively.
Nakon višekratnih oralnih doza ADENURIC, Cmax i AUC su bili 24%, odnosno 12% viši kod žena nego kod muškaraca.
Following multiple-dose oral administration of lamivudine 300 mg once daily for seven days, the mean (CV) steady-state Cmax is 2.04 µg/ml (26%) and the mean (CV) AUC24 is 8.87 µg.h/ml (21%).
Nakon višekratne peroralne primjene lamivudina u dozi od 300 mg jedanput na dan tijekom 7 dana srednji Cmax u stanju dinamičke ravnoteže iznosi 2,04 µg/ml (CV 26%), a srednji AUC24 8,87 µg.h/ml (CV 21%).
Following once daily dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC.
Pri doziranju jednom na dan supkutano, stanje dinamičke ravnoteže razina u plazmi postiže se nakon 3 - 4 dana, uz porast Cmax i AUC od 1,3 puta.
Following once-daily administration of DuoTrav PQ in healthy subjects (N=22) for 5 days, travoprost free acid was not quantifiable in plasma samples from the majority of subjects (94.4%) and generally was not detectable one hour after dosing. .
Nakon primjene jednom dnevno doziranih DuoTrav kapi (polikvaternij-1 kao konzervans) u zdravih ispitanika (N=22) kroz 5 dana, travoprost kao slobodna kiselina nije se mogla izmjeriti u uzorcima plazme većine ispitanika (94,4%) i nije se mogla otkriti ni u jednom uzorku jedan sat nakon doziranja.
Following one-hour IT administration (1 – 10 μg), both cumulative exposure (AUC; range: 83.6 – 608 ng/h/ml) and peak exposure (Cmax; range: 16.4 – 132 ng/ml) values were variable and dose-dependent, but appeared only approximately dose-proportional.
Nakon intratekalne primjene (1 – 10 μg) u trajanju od jednog sata, kumulativna izloženost (AUC; raspon: 83,6 – 608 ng/h/ml) i najviša izloženost (Cmax; raspon: 16,4 – 132 ng/ml) imale su vrijednosti promjenjive i ovisne o dozi, ali činile su se samo približno proporcionalne dozi.
Following oral administration in dogs, oclacitinib maleate is rapidly and well absorbed, with a time to peak plasma concentration (tmax) of less than 1 hour.
Nakon peroralne primjene u pasa, oclacitinib maleat se vrlo brzo i dobro resorbira, s vremenom postizanja najviše koncentracije u plazmi (tmax) manje od jednog sata.
Following oral administration in healthy volunteers, the elimination half-lives of sunitinib and its primary active desethyl metabolite are approximately 40 – 60 hours, and 80 – 110 hours, respectively.
Nakon peroralne primjene u zdravih dobrovoljaca poluvrijeme eliminacije sunitiniba iznosi 40-60 sati, a njegova primarnog aktivnog dezetil-metabolita 80-110 sati.
Following oral administration of 1 mg/kg body weight telmisartan to cats , plasma-concentration-time curves of the parent compound are characterised by rapid absorption, with maximum plasma concentrations (Cmax) achieved after 0.5 hours (tmax).
Nakon peroralne primjene telmisartana u mačaka u dozi od 1 mg/kg tjelesne mase, krivulje plazmatske koncentracije osnovnog spoja u odnosu na vrijeme, obilježava brza apsorpcija uz maksimalnu koncentraciju u plazmi (Cmax) postignutoj nakon 0,5 sati (tmax).
Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the Cmax and AUC were 20% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets.
Nakon peroralne primjene 10 mg apiksabana u obliku 2 zdrobljene tablete od 5 mg s 30 g pirea od jabuka, Cmax i AUC iznosili su 20%, odnosno 16% manje, u usporedbi s primjenom 2 cijele tablete od 5 mg.
Following oral administration of 14C-abiraterone acetate 1,000 mg, approximately 88% of the radioactive dose is recovered in faeces and approximately 5% in urine.
Nakon peroralne primjene 14C-abirateronacetata u dozi od 1000 mg, približno 88% radioaktivne doze nađe se u stolici, a približno 5% u mokraći.
Following oral administration of 14C-abiraterone acetate as capsules, abiraterone acetate is hydrolysed to abiraterone, which then undergoes metabolism including sulphation, hydroxylation and oxidation primarily in the liver.
Nakon peroralne primjene 14C-abirateronacetata u obliku kapsula, abirateronacetat se hidrolizira u abirateron, koji se zatim primarno metabolizira u jetri sulfacijom, hidroksilacijom i oksidacijom.
Following oral administration of 14C-labelled silodosin, the recovery of radioactivity after 7 days was approximately 33.5 % in urine and 54.9 % in faeces.
Nakon peroralne primjene 14C-označenog silodozina, nakon 7 dana se u mokraći otkrilo približno 33,5 % radioaktivnosti, a u stolici približno 54,9 %.
Following oral administration of 825 mg/m2 capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 24% lower AUC for capecitabine than Caucasian patients (n=22).
Nakon peroralne primjene 825 mg/m2 kapecitabina dvaput dnevno tijekom 14 dana, Japanci (n=18) su imali 36% niži Cmax i 24% niži AUC kapecitabina nego bijelci (n=22).
Following oral administration of [14C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose is recovered in the faeces.
Nakon peroralne primjene [14C] vildagliptina oko 85% doze se izlučuje u mokraću, a 15% doze pronađeno je u stolici.
Following oral administration of [14C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose was recovered in the faeces.
Nakon peroralne primjene [14C] vildagliptina oko 85% doze se izlučuje u mokraću, a 15% doze pronađeno je u stolici.
Following oral administration of [14C]-cobicistat, 99% of circulating radioactivity in plasma was unchanged cobicistat.
Nakon peroralne primjene pojačanog [14C]-kobicistata, 99% cirkulirajuće radioaktivnosti u plazmi predstavljao je nepromijenjeni kobicistat.
Following oral administration of [14C]-elvitegravir/ritonavir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary excretion of elvitegravir; 6.7% of the administered dose was recovered in urine.
Nakon peroralne primjene [14C]elvitegravira/ritonavira, 94,8% doze izolirano je u stolici, što je dosljedno s hepatobilijarnom ekskrecijom elvitegravira; 6,7% primijenjene doze izolirano je u urinu.
Following oral administration of [14C]elvitegravir/ritonavir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary elimination of elvitegravir; 6.7% of the administered dose was recovered in urine.
Nakon peroralne primjene [14C]elvitegravira/ritonavira, 94,8% doze izolirano je u stolici, što je dosljedno s hepatobilijarnom eliminacijom elvitegravira; 6,7% primijenjene doze izolirano je u urinu.
Following oral administration of [3-H]-ospemifene, approximately 75% and 7% of the dose was excreted in faeces and urine respectively.
Nakon peroralne primjene [3-H]-ospemifena, približno 75% odnosno 7% doze izlučuje se fecesom odnosno urinom.
Following oral administration of a 100-mg dose to healthy subjects, sitagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post-dose, mean plasma AUC of sitagliptin was 8.52 M•hr, Cmax was 950 nM.
Nakon peroralne primjene doze od 100 mg u zdravih ispitanika, sitagliptin se brzo apsorbira, a vršne koncentracije u plazmi (medijan Tmax) nastupaju 1 do 4 sata nakon doze; srednji AUC sitagliptina u plazmi bilo je 8,52 µM•h, a Cmax 950 nM.
Following oral administration of a single 150 mg dose of bupropion hydrochloride, there was no statistically significant difference in Cmax, half-life, Tmax, AUC, or clearance of bupropion or its active metabolites between smokers and nonsmokers.
Nakon peroralne primjene jedne doze od 150 mg bupropionklorida, nije bilo statistički značajne razlike u Cmax, poluvijeku, Tmax, AUC ili klirensu bupropiona ili njegovih aktivnih metabolitima između pušača i nepušača.
Following oral administration of a single 30 mg dose, ulipristal acetate is rapidly absorbed, with a peak plasma concentration of 176 ± 89 ng/ml occurring approximately 1 hour (0.5-2.0 h) after ingestion, and with an AUC0-∞ of 556 ± 260 ng.h/ml.
Primijenjen peroralno u jednokratnoj dozi od 30 mg, ulipristalacetat se brzo apsorbira dostižući vršnu koncentraciju u plazmi od 176 ± 89 ng/ml oko 1 sat (0,5-2,0 h) nakon ingestije, s AUCR0-∞R od 556 ± 260 ng.h/ml.
Following oral administration of a single dose of ritonavir-boosted [14C]elvitegravir, elvitegravir was the predominant species in plasma, representing approximately 94% and 61% of the circulating radioactivity at 32 and 48 hours, respectively.
Nakon peroralne primjene jednokratne doze ritonavirom pojačanog [14C]elvitegravira, elvitegravir je bio prevladavajuća vrsta u plazmi, predstavljajući oko 94% i 61% cirkulirajuće radioaktivnosti nakon 32, odnosno 48 sati.
Following oral administration of amlodipine/valsartan, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Nakon peroralne primjene amlodipina/valsartana, vršne koncentracije amlodipina i valsartana u plazmi postižu se u 3 odnosno 6–8 sati.
Following oral administration of boosted [14C]elvitegravir, elvitegravir was the predominant species in plasma, representing ~94% of the circulating radioactivity.
Nakon peroralne primjene pojačanog [14C]elvitegravira, elvitegravir je bio prevladavajuća vrsta u plazmi, predstavljajući ~ 94% cirkulirajuće radioaktivnosti.
Following oral administration of C-14 labelled gefitinib to lactating rats 14 days post partum, concentrations of radioactivity in milk were 11-19 fold higher than in blood.
Nakon peroralne primjene C-14 obilježenog gefitiniba u štakorica u laktaciji 14 dana po okotu, koncentracije radioaktivnosti u mlijeku bile su 11-19 puta više nego u krvi.
Following oral administration of cabozantinib, peak cabozantinib plasma concentrations are reached at 2 to 3 hours post-dose.
Nakon peroralne primjene kabozantiniba, vršne koncentracije kabozantiniba u plazmi postignute su za 2 do 3 sata nakon uzimanja doze.
Following oral administration of CoAprovel, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Nakon peroralne primjene lijeka CoAprovel apsolutna oralna bioraspoloživost je 60- 80% za irbesartan, odnosno 50-80% za hidroklorotiazid.
Following oral administration of Copalia, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Nakon peroralne primjene Copalie, vršne koncentracije amlodipina i valsartana u plazmi postižu se u 3 odnosno 6–8 sati.
Following oral administration of CRESEMBA in healthy subjects, the active moiety isavuconazole is absorbed and reaches maximum plasma concentrations (Cmax) approximately 2–3 hours after single and multiple dosing (see Table 3).
Nakon peroralne primjene lijeka CRESEMBA kod zdravih ispitanika, aktivan oblik izavukonazol se apsorbira i postiţe maksimalnu koncentraciju u plazmi (Cmax) oko 2–3 sata nakon primjene jedne ili više doza (vidjeti Tablicu 3).
Following oral administration of Dafiro, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Nakon peroralne primjene Dafira, vršne koncentracije amlodipina i valsartana u plazmi postižu se u 3 odnosno 6–8 sati.
Following oral administration of Dafiro, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Nakon peroralne primjene Dafiroa, vršne koncentracije amlodipina i valsartana u plazmi postižu se u 3 odnosno 6–8 sati.
Following oral administration of Eviplera with food emtricitabine is rapidly and extensively absorbed with maximum plasma concentrations occurring within 2.5 hours post dose.
Nakon peroralne primjene lijeka Eviplera i uz hranu emtricitabin se brzo i opsežno apsorbira i postiže maksimalnu koncentraciju u plazmi u roku od 2,5 sata nakon doziranja.
Following oral administration of Exforge, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6–8 hours, respectively.
Nakon peroralne primjene Exforgea, vršne koncentracije amlodipina i valsartana u plazmi postižu se u 3 odnosno 6–8 sati.
Following oral administration of Ifirmacombi, the absolute oral bioavailability is 60- 80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Nakon peroralne primjene lijeka Ifirmacombi apsolutna oralna bioraspoloživost je 60- 80% za irbesartan, odnosno 50-80% za hidroklorotiazid.
Following oral administration of Irbesartan Hydrochlorothiazide Zentiva, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Nakon peroralne primjene lijeka Irbesartan Hydrochlorothiazide Zentiva apsolutna oralna bioraspoloživost je 60- 80% za irbesartan, odnosno 50-80% za hidroklorotiazid.
Following oral administration of Karvezide, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Nakon peroralne primjene lijeka Karvezide apsolutna oralna bioraspoloživost je 60- 80% za irbesartan, odnosno 50-80% za hidroklorotiazid.
Following oral administration of pimobendan alone the absolute bioavailability of the active ingredient is 60–63%.
Nakon peroralne primjene samog pimobendana, apsolutna bioraspoloživost djelatne tvari je 60 - 63 %.
Following oral administration of radio-labelled isavuconazonium sulfate to healthy subjects, a mean of 46.1% of the radioactive dose was recovered in faeces, and 45.5% was recovered in urine.
Nakon peroralne primjene radioaktivno označenog izavukonazonijevog sulfata kod zdravih ispitanika, utvrĎena je srednja vrijednost od 46,1% radioaktivne doze u fecesu i 45,5% u urinu.
Following oral administration of ritonavir-boosted [14C]elvitegravir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary elimination of elvitegravir; 6.7% of the administered dose was recovered in urine as metabolites.
Nakon peroralne primjene ritonavirom pojačanog [14C]elvitegravira 94,8% doze nađeno je u stolici, što je dosljedno s hepatobilijarnom eliminacijom elvitegravira; 6,7% primijenjene doze nađeno je u urinu u obliku metabolita.
Following oral administration of Stribild with food in HIV-1 infected subjects, peak plasma concentrations were observed 4 hours post-dose for elvitegravir, 3 hours post-dose for cobicistat, 3 hours post-dose for emtricitabine, and 2 hours for tenofovir following the rapid conversion of tenofovir disoproxil fumarate.
Nakon peroralne primjene Stribilda s hranom u pacijenata zaraženih virusom HIV-1, vršne vrijednosti koncentracije u plazmi zapažene su 4 sata nakon doziranja elvitegravira, 3 sata nakon doziranja kobicistata, 3 sata nakon doziranja emtricitabina i 2 sata za tenofovir nakon brze konverzije tenofovirdizoproksilfumarata.
Following oral administration of tablet formulations, in general, dolutegravir exhibited nonlinear pharmacokinetics with less than dose-proportional increases in plasma exposure from 2 to 100 mg; however increase in dolutegravir exposure appears dose proportional from 25 mg to 50 mg for the tablet formulation.
Nakon peroralne primjene lijeka u obliku tablete dolutegravir je u načelu imao nelinearnu farmakokinetiku; izloženost u plazmi povećavala se manje nego proporcionalno dozi kada se ona povećala s 2 na 100 mg; međutim, povećanje izloženosti dolutegraviru čini se proporcionalnim dozi kod primjene tableta u rasponu od 25 mg na 50 mg.
Following oral administration of tenofovir disoproxil fumarate to HIV infected patients, tenofovir disoproxil fumarate is rapidly absorbed and converted to tenofovir.
Nakon peroralne primjene tenofovirdizoproksilfumarata pacijentima zaraženima HIV-om, tenofovirdizoproksil fumarat brzo se apsorbira i konvertira u tenofovir.
Following oral administration of tenofovir disoproxil fumarate to HIV infected patients, tenofovir disoproxil fumarate is rapidly absorbed and converted to tenofovir.
Nakon peroralne primjene tenofovirdizoproksilfumarata u pacijenata zaraženih HIV-om, tenofovirdizoproksilfumarat brzo se apsorbira i pretvara u tenofovir.
Following oral administration of Truvada to healthy subjects, emtricitabine and tenofovir disoproxil fumarate are rapidly absorbed and tenofovir disoproxil fumarate is converted to tenofovir.
Nakon peroralne primjene Truvade u zdravih ispitanika, emtricitabin i tenofovirdizoproksilfumarat se vrlo brzo apsorbiraju, a tenofovirdizoproksilfumarat se pretvara u tenofovir.
Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2-4 hours.
Nakon peroralne primjene samog valsartana, vršne koncentracije valsartana u plazmi postižu se u 2– 4 sata.
Following oral administration the terminal half-life of tenofovir is approximately 12 to 18 hours.
Nakon peroralne primjene, poluvrijeme eliminacije tenofovira iznosi približno 12 do 18 sati.
Following oral administration to healthy male subjects, total radioactivity was excreted primarily in faeces (92% of the administered radiolabelled dose or 99% of the recovered radioactivity) by 168 hours post-dose.
Nakon peroralne primjene u zdravih muških ispitanika, ukupna radioaktivnost prvenstveno se izlučila u feces (92% primijenjene radioaktivno označene doze ili 99% pronađene radioaktivnosti) unutar 168 sati nakon primjene doze.
Following oral administration to pregnant rabbits during the period of organogenesis, asenapine adversely affected body weight at the high dose of 15 mg.kg-1 twice daily.
Nakon peroralne primjene skotnim ženkama kunića tijekom organogeneze, asenapin je imao štetne učinke na tjelesnu masu pri visokoj dozi od 15 mg/kg dvaput na dan.
Following oral administration, agomelatine is rapidly metabolised mainly via hepatic CYP1A2; CYP2C9 and CYP2C19 isoenzymes are also involved but with a low contribution.
Nakon peroralne primjene, agomelatin se brzo metabolizira uglavnom putem CYP1A2 u jetri; CYP2C9 i CYP2C19 izoenzimi također su uključeni, ali oni imaju manji doprinos.